■姜黄素,以其抗炎特性而闻名,选择用于开发消费者友好的成膜喷雾,该喷雾提供姜黄素的精确递送并改善患者的依从性。
■通过溶解姜黄素(1%)制备优化的成膜溶液,EudragitRLPO(5%),丙二醇(1%),和在乙醇:丙酮(20:80)中的樟脑(0.5%)作为溶剂。将该溶液装入含有70%溶液和30%石油气的喷雾容器中。进行体外表征。
■从PubChem数据库中提取潜在的抗炎植物成分,并制备为配体,以及受体分子(nsp10-nsp16),使用AutodockVina进行分子对接。对接研究显示-8.2kcal/mol的最低结合能表明更好的结合亲和力。优化的配方由乙醇:丙酮(20:80)作为溶剂组成,EudragitRLPO(5%)作为聚合物,丙二醇(1%)作为增塑剂,和樟脑油(0.5%)作为渗透促进剂。优化后的配方pH值为5.8±0.01,粘度低,低成膜时间(19.54±0.78秒),药物含量高(8.243±0.43mg/mL),和延长体外药物渗透(85.08±0.09%)9小时。因此,将该制剂掺入使用30%液化石油气的容器中,每次驱动提供0.293±0.08mL,含有1.53±0.07毫克的药物。9小时后,成膜喷雾显示出比市售乳膏制剂和纯药物溶液更高的累积药物渗透(83.94±0.34%),增强率为14。值得注意的是,成膜喷雾显示没有皮肤刺激和保持稳定超过三个月。
■开发的姜黄素成膜系统由于其方便的施用和运输属性而有望作为伤口管理的载体。需要进一步的体内研究来验证其在伤口处理中的功效。
UNASSIGNED: Curcumin, known for its anti-inflammatory properties, was selected for the developing consumer friendly film forming spray that offers precise delivery of curcumin and and improves patient adherence.
UNASSIGNED: An optimized film-forming solution was prepared by dissolving curcumin (1%), Eudragit RLPO (5%), propylene glycol (1%), and camphor (0.5%) in ethanol: acetone (20:80) as the solvent. The solution was filled in a spray container which contained 70% solutions and 30% petroleum gas. In-vitro characterization was performed.
UNASSIGNED: Potential anti-inflammatory phytoconstituents were extracted from the PubChem database and prepared as ligands, along with receptor molecules (nsp10-nsp16), for molecular docking using Autodock Vina. The docking study showed the lowest binding energy of -8.2 kcal/mol indicates better binding affinities. The optimized formulation consisted of ethanol:acetone (20:80) as the solvent, Eudragit RLPO (5%) as the polymer, propylene glycol (1%) as the plasticizer, and camphor oil (0.5%) as the penetration enhancer. The optimized formulation exhibited pH of 5.8 ± 0.01, low viscosity, low film formation time (19.54 ± 0.78 sec), high drug content (8.243 ± 0.43 mg/mL), and extended ex vivo drug permeation (85.08 ± 0.09%) for nine hours. Consequently, the formulation was incorporated into a container using 30% liquefied petroleum gas, delivering 0.293 ± 0.08 mL per actuation, containing 1.53 ± 0.07 mg of the drug. The film-forming spray exhibited higher cumulative drug permeation (83.94 ± 0.34%) than the marketed cream formulation and pure drug solution after 9 h, with an enhancement ratio of 14. Notably, the film-forming spray exhibited no skin irritation and remained stable for over three months.
UNASSIGNED: The developed curcumin film-forming system is promising as a carrier for wound management because of its convenient administration and transport attributes. Further in vivo studies are required to validate its efficacy in wound management.